What Evidence is Available on Aldosterone Antagonists for Use in Heart Failure with Preserved Ejection Fraction? by Loo, Vivian & Tsu, Laura
Chapman University
Chapman University Digital Commons
Pharmacy Faculty Articles and Research School of Pharmacy
2013
What Evidence is Available on Aldosterone
Antagonists for Use in Heart Failure with Preserved
Ejection Fraction?
Vivian Loo
Midwestern University
Laura Tsu
Chapman University, ltsu@chapman.edu
Follow this and additional works at: http://digitalcommons.chapman.edu/pharmacy_articles
Part of the Cardiovascular Diseases Commons, Medical Education Commons, Other Pharmacy
and Pharmaceutical Sciences Commons, and the Science and Mathematics Education Commons
This Article is brought to you for free and open access by the School of Pharmacy at Chapman University Digital Commons. It has been accepted for
inclusion in Pharmacy Faculty Articles and Research by an authorized administrator of Chapman University Digital Commons. For more information,
please contact laughtin@chapman.edu.
Recommended Citation
Loo V, Tsu LV. What evidence is available on aldosterone antagonists for use in heart failure with preserved ejection fraction? Arizona
Journal of Pharmacy 2013;28-30.
What Evidence is Available on Aldosterone Antagonists for Use in Heart
Failure with Preserved Ejection Fraction?
Comments
This article was originally published in Arizona Journal of Pharmacy in 2013. Those receiving articles through
Chapman University Digital Commons may not receive Continuing Education (CE) credit.
Copyright
Arizona Journal of Pharmacy. All rights reserved. This publication may not be republished or re-distributed
without authorization from the Arizona Pharmacy Association.
This article is available at Chapman University Digital Commons: http://digitalcommons.chapman.edu/pharmacy_articles/218
drug iNFormaTioN QuesTioN
Question:  what evidence is available on aldosterone antagonists for use in 
heart failure with preserved ejection fraction?
by Vivian Loo, Pharm.D. Candidate, Class of 2014, and Laura Tsu, Pharm.D., BCPS, Midwestern University College of 
Pharmacy – Glendale
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Answer: 
 
Introduction
Heart failure (HF) is primarily caused by abnormalities 
in cardiac systolic or diastolic function, which dictate the 
prevalence, prognosis, and pharmacotherapy used to treat 
the patient.  Diastolic heart failure can be referred to using 
several interchangeable terms such as HF with normal ejection 
fraction, diastolic dysfunction, or the newest terminology 
being HF with preserved ejection fraction (HFpEF).  HFpEF 
is accountable for over half of HF patients and its prevalence 
depends on various factors, with age being the most important 
determinant.  Several large, randomized, multi-center, double-
blinded trials have been conducted to create guidelines for 
systolic HF treatment, which is also known as HF with 
reduced ejection fraction (HFrEF).  In contrast, few trials have 
been published on the treatment of HFpEF.1,2  Currently, the 
Heart Failure Society of America (HFSA) 2010 guidelines 
recommend the use of diuretics, angiotensin-converting 
enzyme inhibitors (ACEIs), angiotensin receptor blockers 
(ARBs), beta-blockers, and calcium channel blockers as 
possible treatments for HFpEF.3
While there are options for the treatment of HFpEF, most of 
the currently suggested medications for treatment have grade 
C recommendations, which are based on “expert opinion, 
epidemiologic findings from observational studies, and safety 
findings from large-scale use” unless specifically indicated 
for a compelling indication.1,3  The lack of concrete evidence 
and treatment recommendations for HFpEF signals a further 
need for other therapy options, leading to the investigation of 
aldosterone antagonists as a potential treatment option.
Studies have demonstrated that the mineralocorticoid 
aldosterone is stimulated by angiotensin II and activates 
mineralocorticoid receptors to cause sodium retention, 
potassium excretion, endothelial dysfunction, vascular 
inflammation, hypertrophy, and fibrosis—all mechanisms 
that contribute to the pathophysiology of HF.4,5  Despite 
the use of ACEIs in HF treatment, aldosterone levels may 
still potentially increase, indicating that ACEIs may not 
fully suppress angiotensin formation.  Increased levels of 
aldosterone have been associated with impaired functional 
capacity, decreased ventilator response during exercise, and 
an increase in cardiovascular mortality, making aldosterone 
a potential target for HF treatment.5  The 2 most commonly 
used aldosterone antagonists are spironolactone and 
eplerenone.  Spironolactone (Aldactone®) is generically 
available and is a nonselective aldosterone receptor antagonist. 
Its nonselectivity is associated with the adverse effect of 
gynecomastia.  Eplerenone (Inspra®) is a spironolactone 
derivative, is not yet available as a generic, and has higher 
selectivity for the mineralocorticoid receptor with less 
binding to androgen and progesterone receptors compared to 
spironolactone.1,5
Aldosterone antagonists have been proven to be effective 
in the treatment of HFrEF in the Randomized Aldactone 
Evaluation Study (RALES) trial, demonstrating a 31% 
decrease in cardiovascular mortality and a 30% risk reduction 
in all-cause mortality in the spironolactone treatment group 
compared to placebo.  Similarly, the Eplerenone in Mild 
Patients Hospitalization and Survival Study in Heart Failure 
(EMPHASIS-HF) trial evaluated death from cardiovascular 
causes and hospitalization for HF as the primary outcome 
in which the eplerenone treatment group experienced a 
significantly decreased incidence (18.3% eplerenone group 
vs.  25.9% control group).  The treatment group also had a 
statistically significant 38% reduction in hospitalizations for 
HF and demonstrated a decrease in all-cause mortality in 
comparison to the control group.5  The HFSA 2010 guidelines 
strongly recommend (grade A) the use of an aldosterone 
antagonist for New York Heart Association (NYHA) class 
IV HF with left ventricular ejection fraction (LVEF) < 35% 
in addition to standard therapy classified as ACEI/ARB and 
beta-blocker therapy.3  While the RALES and EMPHASIS-HF 
trials have demonstrated a place for aldosterone antagonists 
in HFrEF treatment, aldosterone antagonists have not been 
included in HFpEF treatment guidelines yet.  Spironolactone 
and eplerenone have been further investigated as options for 
HFpEF treatment in 3 clinical trials over the past 2 years.
Clinical Trials
The RAAM-PEF (Randomized Aldosterone Antagonism 
in Heart Failure with Preserved Ejection Fraction) trial was a 
randomized, double-blinded, placebo-controlled, single-center 
study conducted by Deswal et al. comparing eplerenone 25-50 
mg to placebo over 24 weeks in 44 patients.  Investigators 
determined that a sample size of 21 patients in each group 
was necessary to provide 85% power with a 2-tailed α level 
of 0.05 in order to detect differences in endpoints.  The 
primary endpoint was defined as a change in 6-minute 
walk distance (6MWD) from baseline after the 24 weeks of 
randomization and treatment.6  The 6MWD measures the 
distance that a patient can walk on a flat, hard surface in a 
period of 6 minutes to determine functional capacity and 
is predictive of hospitalization rates and mortality in HF 
patients.4,7  Secondary endpoints included echocardiographic 
measurements of diastolic dysfunction, biomarkers such 
as collagen turnover and B-type natriuretic peptide, HF-
related quality of life using the Kansas City Cardiomyopathy 
Questionnaire, and NYHA class.6
drug iNFormaTioN QuesTioN (coNTiNued From Page 28)
Fall 2013 • arizona Journal oF Pharmacy • 29
The results of this study showed an improvement in the 
primary endpoint of 6MWD in both placebo and treatment 
groups, although the difference was not significant (p = 
0.91).  Similarly, all secondary endpoints were not found 
to be statistically significant with the exception of the E/E’ 
ratio and amino-terminal peptide of procollagen type I 
(PINP) and carboxyl-terminal telopeptide of collagen type 
I (CITP) biomarkers.  The E/E’ ratio, which measures left 
ventricular filling pressure and is regarded as the best index 
for detecting diastolic dysfunction in HFpEF, was significantly 
decreased in the eplerenone group (p = 0.01) compared to 
the placebo group, which demonstrated an increase in the 
E/E’ ratio.  The PINP and CITP biomarkers evaluate collagen 
turnover and are used as noninvasive markers to monitor 
the regression of myocardial fibrosis.  At baseline versus 
24 weeks in the eplerenone group, both PINP and CITP 
levels were significantly decreased (p = 0.009 and p = 0.026, 
respectively).  The trial concluded that although eplerenone 
treatment in patients with HFpEF did not improve exercise 
capacity as measured through the 6MWD test, it did result in 
beneficial changes to collagen turnover and diastolic function.6
The Aldo-DHF (The Aldosterone Receptor Blockade in 
Diastolic Heart Failure) trial was a randomized, double-
blinded, placebo-controlled, prospective, multi-center trial 
conducted by Edelmann et al. comparing spironolactone to 
placebo.  Four hundred thirty-three patients were randomized 
to receive spironolactone 25 mg or placebo and were followed 
for approximately 12 months.  Type I and II error rates 
were set at 0.05 (α) and 0.1 (β), respectively, with a power 
of 90% and an estimated sample size of 420 patients.  The 
co-primary endpoints compared spironolactone therapy 
to placebo on diastolic function (E/E’ ratio) and maximal 
exercise capacity (peak VO2) during cardiopulmonary 
exercise testing in patients with HFpEF.  Peak VO2 was 
defined by the study as the maximum value of the last three 
10-second averages during exercise.  Secondary endpoints 
included echocardiographic measures of cardiac function 
and remodeling, submaximal and maximal exercise capacity, 
serum biomarkers, quality of life, morbidity, and mortality.4
The results of the Aldo-DHF trial showed an improvement 
in the primary endpoint of diastolic dysfunction as measured 
by the E/E’ ratio.  Echocardiographic results of the treatment 
group showed a decrease in the E/E’ ratio after 12 months 
compared to placebo (95% CI, -2.0 to -0.9, p < 0.001).  The 
primary endpoint of maximal exercise capacity did not differ 
significantly between the treatment and placebo group after 
12 months (p = 0.81).  Other secondary endpoints of note 
in the spironolactone group versus placebo group included 
an increase in LVEF (95% CI, 0.1 to 3.1, p = 0.04), increase 
in 6MWD (95% CI, -27 to -2, p = 0.02), decrease in left 
ventricular mass index (95% CI, -10 to -1, p = 0.009), and 
decrease in left ventricular end diastolic diameter (95% 
CI, -2.5 to -0.3, p = 0.01).  The study also acknowledged 
that it was not adequately powered to assess the secondary 
endpoints of morbidity and mortality.  The trial concluded 
that spironolactone treatment in HFpEF patients improved 
diastolic function and left ventricular function but had no 
effect on maximal exercise capacity.4
The clinical study TOPCAT (Treatment Of Preserved 
Cardiac Function Heart Failure with an Aldosterone 
Antagonist) is a multi-center, international, randomized, 
double-blinded, placebo-controlled trial using 15-45 mg of 
spironolactone.  The study was conducted with 3,445 subjects 
aged 50 years or older, recruited from over 200 clinical 
centers, with HF and LVEF ≥ 45%, HFpEF, controlled systolic 
blood pressure, and a serum potassium < 5.0 mEq/L.  The 
primary endpoint was a composite of cardiovascular mortality, 
aborted cardiac arrest, or hospitalization for the management 
of HF.  Secondary endpoints included all-cause mortality, new 
onset of diabetes mellitus or atrial fibrillation, and quality of 
life.  The study ended in January of 2012 and the results are 
expected to be published in the near future.8 
Discussion
The RAAM-PEF and Aldo-DHF trials found that 
aldosterone antagonist use in patients with HFpEF improved 
diastolic dysfunction as measured by the E/E’ ratio.  However, 
according to the Aldo-DHF trial, there is currently no accepted 
minimal clinically important difference in E/E’ that should be 
achieved to alter the prognosis of HFpEF.4 Both trials also 
studied exercise capacity as measured by the 6MWD.  The 
RAAM-PEF trial, which evaluated patients after 6 months 
of therapy, did not find a statistically significant difference 
between the eplerenone and placebo group while the Aldo-
DHF trial, which evaluated patients after 12 months, found 
a marked improvement in the spironolactone group.  The 
difference in these results may be attributed to the length 
of the 2 trials in which the RAAM-PEF trial may not have 
had adequate time for eplerenone to exert a clinical effect 
on 6MWD.  It is also important to note that the RALES and 
EMPHASIS-HF trials evaluated aldosterone antagonists in 
HFrEF patients through the primary outcomes of differences 
in morbidity and mortality.  In contrast, the RAAM-PEF 
and Aldo-DHF trials were only able to evaluate surrogate 
markers of morbidity and mortality in HFpEF such as diastolic 
function and exercise capacity.
In addition, the populations in both trials consisted mainly 
of NYHA class II patients.  Therefore, the results of these 
studies may not be generalizable to sicker populations in the 
NYHA class III and IV categories.  Also, RAAM-PEF was 
studied at the Veterans Affairs Medical Center in Houston, 
Texas, and all but 3 patients were male, indicating that the 
results are most applicable to men.
There is also concern with the risk of hyperkalemia 
because a major adverse effect of aldosterone antagonists 
is an elevation in potassium levels.  Most, if not all, HF 
patients’ medication lists include an ACEI/ARB to prevent 
cardiac remodeling.  The combination of an ACEI/ARB with 
an aldosterone antagonist may potentially increase the risk 
of an elevated potassium level leading to hyperkalemia and 
subsequent arrhythmias.  In both trials, a nonstatistically 
significant difference was found between groups in the 
development of hyperkalemia, defined as a serum potassium ≥ 
5.5 mEq/L.3,5  Thus, it can be concluded that with appropriate 
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and routine laboratory monitoring of serum potassium levels, 
aldosterone antagonists can be safely used in HFpEF patients 
who are on concurrent ACEI/ARB therapy.
Based on the evidence provided by RAAM-PEF and 
AldoDHF, an aldosterone antagonist may be a potential 
additive therapy for HFpEF if the patient’s blood pressure 
and heart rate are controlled and serum potassium levels 
are carefully monitored.  While these trials have shown 
improvement in diastolic function and potential increases in 
exercise capacity, the effects of aldosterone antagonists on 
the long-term morbidity and mortality of HFpEF patients still 
remains to be seen as investigated through the TOPCAT trial.  
The results of the TOPCAT trial will provide more evidence 
about aldosterone antagonist use in HFpEF due to its clinical 
endpoints.
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